Fecal Microbiota Transplantation in Inflammatory Bowel Disease Biomedicines. 2023 Mar 27;11(4):1016. doi: 10.3390/biomedicines11041016.
Adrian Boicean 1 2, Victoria Birlutiu 1 2, Cristian Ichim 1 2, Paula Anderco 2, Sabrina Birsan 1 2 |
Author information 1County Clinical Emergency Hospital of Sibiu, 550245 Sibiu, Romania. 2Faculty of Medicine, Lucian Blaga University of Sibiu, 550169 Sibiu, Romania. Abstract Inflammatory bowel diseases represent a complex array of diseases of incompletely known etiology that led to gastrointestinal tract chronic inflammation. In inflammatory bowel disease, a promising method of treatment is represented by fecal microbiota transplantation (FMT), FMT has shown its increasing effectiveness and safety in recent years for recurrent CDI; moreover, it showed real clinical benefits in treating SARS-CoV-2 and CDI co-infection. Crohn's disease and ulcerative colitis are characterized by immune dysregulation, resulting in digestive tract damage caused by immune responses. Most current therapeutic strategies are associated with high costs and many adverse effects by directly targeting the immune response, so modifying the microbial environment by FMT offers an alternative approach that could indirectly influence the host's immune system in a safe way. Studies outline the endoscopic and clinical improvements in UC and CD in FMT patients versus control groups. This review outlines the multiple benefits of FMT in the case of IBD by improving patients unbalanced gut, therefore improving endoscopic and clinical symptomatology. We aim to emphasize the clinical importance and benefits of FMT in order to prevent flares or complications of IBD and to highlight that further validation is needed for establishing a clinical protocol for FMT in IBD.
|
© Copyright 2013-2024 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only.
Use of this website is governed by the GIHF terms of use and privacy statement.